Neuromyelitis optica (NMO, or Devic's disease) is an autoimmune inflammatory disease of the central nervous system (CNS) that is typically associated with severe attacks of optic neuritis and myelitis and characteristically spares the brain early in the disease course.
Diagnosis and Treatment of Neuromyelitis Optica
Neuromyelitis optica (NMO, or Devic's disease) is an autoimmune inflammatory disease of the central nervous system (CNS) that is typically associated with severe attacks of optic neuritis and myelitis and characteristically spares the brain early in the disease course.
Although historically believed to be distinct from multiple sclerosis (MS) in that it presented with simultaneous or rapidly sequential optic neuritis and myelitis with a short interval, it is now believed that it usually begins with unilateral optic neuritis or myelitis and follows a relapsing course. 1 In the past, the relapsing form of NMO was typically diagnosed as MS, based on the principle that relapsing CNS inflammatory disease was by definition MS. Over the last decade, however, studies of the clinical aspects, natural history, neuroimaging, pathology and immunology of NMO have established that it is distinct from prototypic MS.
1,2 A specific immunoglobulin G (IgG1) autoantibody, NMO-IgG, was discovered in NMO patients 3 that subsequently was shown to target the astrocytic water channel aquaporin-4 (AQP4). 4 This advance has facilitated early recognition of NMO 5, 6 and its differentiation from MS, appreciation of a broader spectrum of manifestation, including limited forms of NMO (e.g. recurrent optic neuritis and recurrent transverse myelitis), and, perhaps most importantly, has facilitated breakthrough research in understanding NMO pathogenesis. 
Diagnosis

Demographics and Clinical Characteristics
index episodes and the requirement of monophasic course, which were historically important distinguishing features from MS. In addition to optic neuritis and transverse myelitis that alone do not distinguish between NMO and MS, however, added specificity criteria were incorporated, the most important of which was the presence of a 'longitudinally extensive spinal cord lesion.' This is defined as a T2 signal lesion extending over three or more vertebral segments in the context of an acute myelitis attack on magnetic resonance imaging (MRI) scan (see Figure 1 ).
1
Asymptomatic (but not symptomatic) brain lesions detected on MRI were allowed. NMO-IgG seropositivity 3 and the observation that symptomatic brain lesions are compatible with a diagnosis of NMO led to the revision of the criteria in 2006 13 (see Table 1 ). The essential clinical features of NMO are optic neuritis and myelitis, which are usually more disabling in NMO than when they occur in the context of MS. 1 Myelitis attacks are frequently 'complete' (symmetrical and with motor, sensory and sphincter involvement) rather than 'partial.' NMO optic neuritis attacks are more frequently bilateral with persisting visual deficits more severe than in MS. Brainstem syndromes are now recognized to be especially common. Severe and intractable hiccups, nausea, and vomiting lasting weeks to months may occur and may be the presenting symptom in patients with NMO. 1, 14, 15 Occasionally patients may experience encephalopathy due to transient vasogenic brain edema and may be diagnosed as having posterior reversible leukoencephalopathy. 16 Neurological disability in NMO is related to the attacks and a secondary progressive course is very uncommon, unlike MS. were 73 and 91%, respectively, for NMO versus MS, the entity with which NMO is most commonly confused. 3 Several independent investigators have confirmed the presence of NMO-IgG using a variety of assays for anti-AQP4 antibody detection.
20-24
Diagnosis and Treatment of Neuromyelitis Optica 57 
